Table 1. Demographic and clinical characteristics of COVID-19 patients.
Variables | Value (N = 384) |
Demographics | |
Age (years) | 59 (23) |
Sex (male%) | 179 (46.6%) |
Comorbidities | |
Hypertension | 123 (32.0%) |
Diabetes | 54 (14.1%) |
Coronary heart disease | 27 (7.0%) |
Symptoms | |
Fever | 299 (77.9%) |
Cough | 240 (62.5%) |
Expectoration | 94 (24.5%) |
Pharyngalgia | 18 (4.7%) |
Fatigue | 128 (33.3%) |
Dyspena | 54 (14.1%) |
Disease severity | |
Mild / Severe / Critical group | 157 / 129/ 15 |
Antiviral treatment | |
With abidor | 258 (67.2%) |
With Lianhua Qingwen | 199 (51.8%) |
With oseltamivir capsules | 68 (17.7%) |
With hydroxychloroquine, or chloroquine | 95 (24.7%) |
With ribavirin | 135 (35.2%) |
With glucocorticoid | 113 (29.4%) |
Laboratory detections | |
Leukocyte count (10 9 /L) | 5.2 (4.3) |
Lymphocyte (10 9 /L) | 0.9 (0.3) |
Platelet count (10 9 /L) | 268 ± 133 |
Serum bilirubin (μmol/l) | 27 ± 20 |
Creatinine (μmol / L) | 55 (28) |
Outcome | |
Duration of detectable viral RNA in sputum (days) | 32 ± 21 |
Data are expressed as the mean ± standard deviation, median (interquartile range) or number (percent). Comparisons between groups were performed using one-way ANOVA, the Mann–Whitney U test, or a chi-squared test.